Preview post hoc analyses of a weight-loss medication’s effects across sleep apnea, asthma outcomes, blood pressure, and liver health at a major diabetes meeting.
Key Takeaways
- Semaglutide 2.4 mg halved incident obstructive sleep apnea risk versus placebo (HR 0.48)
- Asthma-related adverse events were lower with semaglutide, HR 0.58 versus placebo
- Semaglutide produced systolic blood pressure reductions versus placebo of about 5.5 mmHg